Arginase activity in alternatively activated macrophages protects PI3Kp110δ deficient mice from dextran sodium sulfate induced intestinal inflammation

European Journal of Immunology

Volumn 44, Issue 11, 2014, Pages 3353-3367

  Weisser, Shelley B ^a,b   Kozicky, Lisa K ^a,b   Brugger, Hayley K ^a,b   Ngoh, Eyler N ^a,b   Cheung, Bonnie ^a,b   Jen, Roger ^a,b   Menzies, Susan C ^a,b   Samarakoon, Asanga ^a   Murray, Peter J ^c   Lim, C James ^a,b   Johnson, Pauline ^a   Boucher, Jean Luc ^d   van Rooijen, Nico ^e   Sly, Laura M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Alternatively activated macrophages; Arginase; Colitis; DSS induced intestinal inflammation; PI3Kp110

Indexed keywords

ARG1 PROTEIN, MOUSE; ARGINASE; DEXTRAN SULFATE; INTERLEUKIN 4; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CD PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; COLON; DEFICIENCY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; PATHOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ARGINASE; COLITIS; COLON; DEXTRAN SULFATE; INFLAMMATION; INTERLEUKIN-4; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84916908894     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343981     Document Type: Article

References (50)

1. Latella, G. and Papi, C., Crucial steps in the natural history of inflammatory bowel disease. World J. Gastroenterol. 2012. 18: 3790-3799.
2. Rocchi, A., Benchimol, E. I., Bernstein, C. N., Bitton, A., Feagan, B., Panaccione, R., Glasgow, K. W. et al., Inflammatory bowel disease: a Canadian burden of illness review. Can. J. Gastroenterol. 2012. 26: 811-817.
3. Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I. et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012. 142: 46-54 e42; quiz e30.
4. Sandborn, W. J., State-of-the-art: immunosuppression and biologic therapy. Dig. Dis. 2010. 28: 536-542.
5. Perse, M. and Cerar, A., Dextran sodium sulphate colitis mouse model: traps and tricks. J. Biomed. Biotechnol. 2012. 2012: 718617.
6. Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M. F., Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007. 2: 541-546.
7. Podolsky, D. K., Inflammatory bowel disease. N. Engl. J. Med. 2002. 347: 417-429.
8. Heinsbroek, S. E. and Gordon, S., The role of macrophages in inflammatory bowel diseases. Expert Rev. Mol. Med. 2009. 11: e14.
9. Martinez, F. O., Helming, L. and Gordon, S., Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009. 27: 451-483.
10. Sica, A. and Mantovani, A., Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012. 122: 787-795.
11. Weisser, S. B., Brugger, H. K., Voglmaier, N. S., McLarren, K. W., van Rooijen, N. and Sly, L. M., SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J. Leukoc. Biol. 2011. 90: 483-492.
12. Hunter, M. M., Wang, A., Parhar, K. S., Johnston, M. J., Van Rooijen, N., Beck, P. L. and McKay, D. M., In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 2010. 138: 1395-1405.
13. Cassetta, L., Cassol, E. and Poli, G., Macrophage polarization in health and disease. Sci. World J. 2011. 11: 2391-2402.
14. Weisser, S. B., McLarren, K. W., Voglmaier, N., van Netten-Thomas, C. J., Antov, A., Flavell, R. A. and Sly, L. M., Alternative activation of macrophages by IL-4 requires SHIP degradation. Eur. J. Immunol. 2011. 41: 1742-1753.
15. Ghigo, A., Damilano, F., Braccini, L. and Hirsch, E., PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010. 32: 185-196.
16. Okkenhaug, K., Patton, D. T., Bilancio, A., Garcon, F., Rowan, W. C. and Vanhaesebroeck, B., The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 2006. 177: 5122-5128.
17. Fung-Leung, W. P., Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function. Cell Signal. 2011. 23: 603-608.
18. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W. et al., Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002. 297: 1031-1034.
19. Uno, J. K., Rao, K. N., Matsuoka, K., Sheikh, S. Z., Kobayashi, T., Li, F., Steinbach, E. C. et al., Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta. Gastroenterology 2010. 139: 1642-1653.
20. Qualls, J. E., Kaplan, A. M., van Rooijen, N. and Cohen, D. A., Suppression of experimental colitis by intestinal mononuclear phagocytes. J. Leukoc. Biol. 2006. 80: 802-815.
21. Weisser, S. B., McLarren, K. W., Kuroda, E. and Sly, L. M., Generation and characterization of murine alternatively activated macrophages. Methods Mol. Biol. 2013. 946: 225-239.
22. McLarren, K. W., Cole, A. E., Weisser, S. B., Voglmaier, N. S., Conlin, V. S., Jacobson, K., Popescu, O. et al., SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am. J. Pathol. 2011. 179: 180-188.
23. El Kasmi, K. C., Qualls, J. E., Pesce, J. T., Smith, A. M., Thompson, R. W., Henao-Tamayo, M., Basaraba, R. J. et al., Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 2008. 9: 1399-1406.
24. Summers, R. W., Elliott, D. E., Urban, J. F., Jr., Thompson, R. and Weinstock, J. V., Trichuris suis therapy in Crohn's disease. Gut 2005. 54: 87-90.
25. Summers, R. W., Elliott, D. E., Urban, J. F., Jr., Thompson, R. A. and Weinstock, J. V., Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005. 128: 825-832.
26. Croese, J., O'Neil, J., Masson, J., Cooke, S., Melrose, W., Pritchard, D. and Speare, R., A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006. 55: 136-137.
27. Jenkins, S. J., Ruckerl, D., Cook, P. C., Jones, L. H., Finkelman, F. D., van Rooijen, N., MacDonald, A. S. et al., Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011. 332: 1284-1288.
28. Schreiber, S., Heinig, T., Panzer, U., Reinking, R., Bouchard, A., Stahl, P. D. and Raedler, A., Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995. 108: 21-33.
29. Elrod, J. W., Laroux, F. S., Houghton, J., Carpenter, A., Ando, T., Jennings, M. H., Grisham, M. et al., DSS-induced colitis is exacerbated in STAT-6 knockout mice. Inflamm. Bowel Dis. 2005. 11: 883-889.
30. Heller, N. M., Qi, X., Junttila, I. S., Shirey, K. A., Vogel, S. N., Paul, W. E. and Keegan, A. D., Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci. Signal. 2008. 1: ra17.
31. Gray, M. J., Poljakovic, M., Kepka-Lenhart, D. and Morris, S. M., Jr., Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 2005. 353: 98-106.
32. Ruffell, D., Mourkioti, F., Gambardella, A., Kirstetter, P., Lopez, R. G., Rosenthal, N. and Nerlov, C., A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. USA 2009. 106: 17475-17480.
33. Pauleau, A. L., Rutschman, R., Lang, R., Pernis, A., Watowich, S. S. and Murray, P. J., Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 2004. 172: 7565-7573.
34. Hazeki, K., Nigorikawa, K. and Hazeki, O., Role of phosphoinositide 3-kinase in innate immunity. Biol. Pharm. Bull. 2007. 30: 1617-1623.
35. Han, S., Ritzenthaler, J. D., Wingerd, B. and Roman, J., Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J. Biol. Chem. 2005. 280: 33240-33249.
36. Leung, G., Wang, A., Fernando, M., Phan, V. C. and McKay, D. M., Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. Am. J. Physiol. Gastrointest. Liver Physiol. 2013. 304: G781-G792.
37. Gobert, A. P., Cheng, Y., Akhtar, M., Mersey, B. D., Blumberg, D. R., Cross, R. K., Chaturvedi, R. et al., Protective role of arginase in a mouse model of colitis. J. Immunol. 2004. 173: 2109-2117.
38. Pesce, J. T., Ramalingam, T. R., Mentink-Kane, M. M., Wilson, M. S., El Kasmi, K. C., Smith, A. M., Thompson, R. W. et al., Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009. 5: e1000371.
39. Akazawa, Y., Kubo, M., Zhang, R., Matsumoto, K., Yan, F., Setiawan, H., Takahashi, H. et al., Inhibition of arginase ameliorates experimental ulcerative colitis in mice. Free Radic. Res. 2013. 47: 137-145.
40. Aoi, Y., Terashima, S., Ogura, M., Nishio, H., Kato, S. and Takeuchi, K., Roles of nitric oxide (NO) and NO synthases in healing of dextran sulfate sodium-induced rat colitis. J. Physiol. Pharmacol. 2008. 59: 315-336.
41. Coburn, L. A., Gong, X., Singh, K., Asim, M., Scull, B. P., Allaman, M. M., Williams, C. S. et al., L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS ONE 2012. 7: e33546.
42. Muratov, V., Lundahl, J., Mandic-Havelka, A., Elvin, K., Ost, A., Shizume, Y., Furuya, K. et al., Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study. J. Clin. Apher. 2010. 25: 287-293.
43. Lindberg, A., Eberhardson, M., Karlsson, M. and Karlen, P., Long-term follow-up with granulocyte and monocyte apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010. 10: 73.
44. Fukunaga, K., Yokoyama, Y., Kamikozuru, K., Yoshida, K., Kikuyama, R., Nagase, K., Nakamura, S., et al., Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. J. Clin. Apher. 2010. 25: 226-228.
45. Fleming, B. D. and Mosser, D. M., Regulatory macrophages: setting the threshold for therapy. Eur. J. Immunol. 2011. 41: 2498-2502.
46. Murray, P. J. and Wynn, T. A., Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 2011. 89: 557-563.
47. Itzkowitz, S. H. and Yio, X., Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004. 287: G7-G17.
48. Erreni, M., Mantovani, A. and Allavena, P., Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011. 4: 141-154.
49. Van Rooijen, N. and Sanders, A., Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994. 174: 83-93.
50. Kim, N. N., Cox, J. D., Baggio, R. F., Emig, F. A., Mistry, S. K., Harper, S. L., Speicher, D. W. et al., Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001. 40: 2678-2688.